Analyzing Mazor Robotics (MZOR) and Edwards Lifesciences Corporation (EW)
Mazor Robotics (NASDAQ: MZOR) and Edwards Lifesciences Corporation (NYSE:EW) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, dividends, valuation and earnings.
Risk & Volatility
Mazor Robotics has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. Comparatively, Edwards Lifesciences Corporation has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500.
Valuation & Earnings
This table compares Mazor Robotics and Edwards Lifesciences Corporation’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Mazor Robotics||$36.38 million||42.01||-$18.66 million||($0.79)||-75.81|
|Edwards Lifesciences Corporation||$2.96 billion||7.24||$569.50 million||$3.44||29.47|
Edwards Lifesciences Corporation has higher revenue and earnings than Mazor Robotics. Mazor Robotics is trading at a lower price-to-earnings ratio than Edwards Lifesciences Corporation, indicating that it is currently the more affordable of the two stocks.
This is a summary of current recommendations for Mazor Robotics and Edwards Lifesciences Corporation, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Edwards Lifesciences Corporation||0||5||15||1||2.81|
Mazor Robotics presently has a consensus price target of $39.60, indicating a potential downside of 33.88%. Edwards Lifesciences Corporation has a consensus price target of $124.95, indicating a potential upside of 23.25%. Given Edwards Lifesciences Corporation’s stronger consensus rating and higher possible upside, analysts clearly believe Edwards Lifesciences Corporation is more favorable than Mazor Robotics.
Insider & Institutional Ownership
25.7% of Mazor Robotics shares are held by institutional investors. Comparatively, 82.4% of Edwards Lifesciences Corporation shares are held by institutional investors. 2.1% of Edwards Lifesciences Corporation shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This table compares Mazor Robotics and Edwards Lifesciences Corporation’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Edwards Lifesciences Corporation||22.47%||27.22%||15.67%|
Edwards Lifesciences Corporation beats Mazor Robotics on 12 of the 14 factors compared between the two stocks.
Mazor Robotics Company Profile
Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications. Its Renaissance System and its predecessor are used in a number of spine surgeries, including fusion, correction of spinal deformities, biopsy collection, tumor excision and cement augmentations. Furthermore the Company developed the Renaissance Brain Module, an application of its Renaissance System that provides control over the insertion of surgical instruments during brain surgery.
Edwards Lifesciences Corporation Company Profile
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World. Its products are categorized into three areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care. It also develops hemodynamic monitoring systems that are used to measure a patient’s cardiovascular function in the hospital setting. It is developing products, such as the Edwards SAPIEN 3 Ultra System and Edwards SAPIEN XT transcatheter heart valve, among others. Its Transcatheter Heart Valve Therapy and Surgical Heart Valve Therapy products are manufactured in the United States, Singapore and Switzerland. Critical Care products are manufactured in its facilities located in Puerto Rico and the Dominican Republic.
Receive News & Ratings for Mazor Robotics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.